Provenance Record

Well-structured article with appropriate technical depth. Clear Overview/What We Know/What We Don't Know/Analysis format. Neutral tone throughout. Word count (800) sits at the upper boundary of the News category range (400-1200). No AI self-reference, no sensationalism.

Three sources cited. Source-0 (BusinessWire via Archive.org fallback, source-0.html.gz): fully read; confirms FDA accelerated approval on May 22, 2026 as first US HDV treatment, MYR301 Phase 3 study, Dr. Dietmar Berger quote verbatim, 40,000-80,000 US patients, 2%-4% of HBV patients, 12 million worldwide, 50% five-year mortality in cirrhotic patients, mechanism as entry inhibitor, 8.5 mg once-daily subcutaneous injection, adverse reactions (injection site reactions, headache, abdominal pain, fatigue, pruritus), boxed warning on post-discontinuation exacerbations, and anaphylaxis warning. Source-1 (EMA, ema.europa.eu): snapshot failed with Timeout after 15000ms — no file captured. Claims attributed to EMA include: (a) mechanism quote 'attaching to and blocking a receptor through which the hepatitis delta and hepatitis B viruses enter liver cells', (b) 48% (24/50) HDV RNA clearance rate at 48 weeks vs. 2% (1/51) in untreated patients, (c) conditional marketing authorisation granted July 31, 2020, converted to standard authorisation July 18, 2023. These claims are plausible and consistent with Hepcludex's known regulatory history but cannot be verified from available snapshot. Source-2 (BioSpace, source-2.html.gz): fully read; carries the same Gilead press release as BusinessWire. The article attributes 'Breakthrough Therapy Designation, Orphan-Drug Designation, and Priority Review' to BioSpace, but these designations are not present in the BioSpace snapshot. Neither are they present in the BusinessWire snapshot. These designations are commonly part of Gilead press release materials for Hepcludex but were not captured in the available snapshots. This is a minor misattribution of source (facts may be accurate but the specific source citation is not confirmed).

Headline, summary, and lead are fully supported by the BusinessWire snapshot. The Dr. Berger quote is reproduced verbatim. The mechanism description from BusinessWire is accurate. The key concern is that EMA-attributed claims (specific 48% response rate, EU authorization dates) cannot be verified from disk due to snapshot failure, and FDA designation claims attributed to BioSpace are not found in the BioSpace snapshot.

Substantively solid article covering a genuine first-ever FDA approval for a rare liver disease. The headline and lead are fully sourced and confirmed. Two recoverable issues exist in the body: EMA-attributed statistics and dates that cannot be verified due to snapshot failure, and FDA designation claims attributed to BioSpace that are not in that source. Both issues are recoverable via corrections record. Article approved with corrections.